ANLN and TLE2 in muscle invasive bladder cancer

• Verfasst von: Wu, Sheng [VerfasserIn]
• Verfasst von: Nitschke, Katja [VerfasserIn]
• Verfasst von: Heinkele, Jakob [VerfasserIn]
• Verfasst von: Weis, Cleo-Aron Thias [VerfasserIn]
• Verfasst von: Worst, Thomas [VerfasserIn]
• Verfasst von: Eckstein, Markus [VerfasserIn]
• Verfasst von: Porubský, Štefan [VerfasserIn]
• Verfasst von: Erben, Philipp [VerfasserIn]
• Titel: ANLN and TLE2 in muscle invasive bladder cancer
• Titelzusatz: a functional and clinical evaluation based on in silico and in vitro data
• Verf.angabe: Sheng Wu, Katja Nitschke, Jakob Heinkele, Cleo-Aron Weis, Thomas Stefan Worst, Markus Eckstein, Stefan Porubsky and Philipp Erben
• E-Jahr: 2019
• Jahr: 21 November 2019
• Umfang: 16 S.
• Fussnoten: Gesehen am 05.05.2020
• Titel Quelle: Enthalten in: Cancers
• Ort Quelle: Basel : MDPI, 2009
• Jahr Quelle: 2019
• Band/Heft Quelle: 11(2019,12) Artikel-Nummer 1840, 16 Seiten
• ISSN Quelle: 2072-6694
• DOI: doi:10.3390/cancers11121840
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: biomarker
• Sach-SW: molecular subtype
• Sach-SW: muscle invasive bladder cancer
• Sach-SW: prognosis
• K10plus-PPN: 1697250475
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext

Abstract

Anilin actin binding protein (ANLN) and transducing-like enhancer protein 2 (TLE2) are associated with cancer patient survival and progression. The impact of their gene expression on progression-free survival (PFS) of patients with muscle invasive bladder cancer (MIBC) treated with radical cystectomy (RC) and subtype association has not yet been investigated. qRT-PCR was used to measure the transcript levels of ANLN and TLE2 in the Mannheim cohort, and validated in silico by The Cancer Genome Atlas (TCGA) cohort. Uni- and multivariate Cox regression analyses identified predictors for disease-specific survival (DSS) and overall survival (OS). In the Mannheim cohort, tumors with high ANLN expression were associated with lower OS and DSS, while high TLE2 expression was associated with a favorable OS. The TCGA cohort confirmed that high ANLN and low TLE2 expression was associated with shorter OS and disease-free survival (DFS). In both cohorts, multivariate analyses showed ANLN and TLE2 expression as independent outcome predictors. Furthermore, ANLN was more highly expressed in cell lines and patients with the basal subtype, while TLE2 expression was higher in cell lines and patients with the luminal subtype. ANLN and TLE2 are promising biomarkers for individualized bladder cancer therapy including cancer subclassification and informed MIBC prognosis.